Genome

Twist Bioscience Launches IVDR-compliant Precision Dx Products for Whole Exome Sequencing

Retrieved on: 
Tuesday, March 5, 2024
Research, Other Health, Pharmaceutical, Technology, Medical Devices, Genetics, Health Technology, Science, Nanotechnology, Biotechnology, Medical Supplies, Health, Other Science, Twist Bioscience, Twist, Reagent, Silicon, IVDR, NGS, Documentation, Doctor of Philosophy, Safety, Certification, Exon, Genome, Laboratory, DNA, IVD, Workflow, Medical device

The suite of our CE-marked Products includes:

Key Points: 
  • The suite of our CE-marked Products includes:
    The Twist Precision Prep and Enrichment Dx Kit1 (Reagents for enzymatic fragmentation, library preparation, and target enrichment), which is panel-agnostic2
    Twist Precision Exome Dx Kit1 (Reagents for enzymatic fragmentation, library preparation, and target enrichment along with targeted capture probes for exome enrichment; IVDR compliant workflow)
    The Twist Precision Prep and Enrichment Dx Kit and the Twist Precision Exome Dx Panel can be used individually within existing workflows or as a combined solution known as the Twist Precision Exome Dx Kit.
  • “The Twist Precision Dx products are our first NGS product line specifically developed to be included within regulated customer products.
  • The Twist Precision Exome Dx Panel1 is a qualified Twist DNA panel that can be used in conjunction with the Twist Precision Prep and Enrichment Dx kit to produce exome-enriched libraries compatible for NGS applications.
  • Twist Precision Exome Dx Kit1 utilizes the qualified Twist Precision Exome Dx Panel along with the Twist Precision Prep and Enrichment Dx Kit to produce exome-enriched libraries compatible for NGS applications.

Global Metagenomic Market Research 2024-2028: A Game Changer in Diagnostics - New Technology Changes Viewpoint on Infections - ResearchAndMarkets.com

Retrieved on: 
Friday, March 1, 2024
Health Technology, Health, Medical Devices, Infection, Metagenomics, Chronic condition, Genetics, Genome, Genetic testing, Knowledge, Disease, Research report, Research, Cancer

The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User 2024 to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Metagenomic Markets: Global Market Analysis with Forecasts by Applications, Technologies, Product and User 2024 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Learn all about it in this new research report.
  • This report looks at the technology, the applications, the users and the types of products that will be sold.
  • Get our research team working for you by ordering all, or a portion, of this comprehensive report.

European UPC Court of Appeal Overturns Injunction Impacting NanoString’s CosMx Products, Company to Immediately Resume Sales in 16 EU Countries

Retrieved on: 
Monday, February 26, 2024
Research, Professional Services, Patent Law, Technology, Genetics, Health Technology, Science, Legal, Biotechnology, Other Technology, Other Science, Health, SMI, OTC, Harvard University, Sale, UPC, Hardship, Genetic, Lifting, Patent, NanoString Technologies, Genome, News, Patient, Genetic engineering, Mary Ann Liebert

The decision allows NanoString to immediately resume sales of all CosMx products in 16 impacted UPC member countries.

Key Points: 
  • The decision allows NanoString to immediately resume sales of all CosMx products in 16 impacted UPC member countries.
  • “We believe that with today’s decision, the tide is turning in favor of NanoString and scientific freedom.
  • NanoString is evaluating its next steps in Germany in light of today’s decision from the UPC and for now the German injunction remains in place.
  • The CosMx SMI platform has been installed at approximately 180 customer sites to date.

Comprehensive Study from 50 Top Scientists Details Five Cutting-edge Advances in Biomedical Engineering and Their Applications in Medicine

Retrieved on: 
Thursday, February 22, 2024
Health Technology, Data Management, Technology, Nanotechnology, Stem Cells, Biometrics, Medical Devices, Neurology, Genetics, Artificial Intelligence, Science, Biotechnology, Other Science, Health, Research, Paper, Therapy, Tissue engineering, Transcriptome, Gene editing, AI, Education, Substance abuse, Immunotherapy, Epigenome, Growth, Physiology, Interface, Cell, Vaccine, Behavior, Protein engineering, Biomedicine, University, Biomedical engineering, Guideline, Biological engineering, Patient, Genome, Johns Hopkins University, Genomics, Diagnosis, Tissue, DNA, Immune system, Brain, Medical imaging

Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.

Key Points: 
  • Through the course of the workshop, the researchers identified five primary medical challenges that have yet to be addressed, but, by solving them with advanced biomedical engineering approaches, can greatly improve human health.
  • By focusing on these five areas, the consortium has laid out a roadmap for future research and funding.
  • Advanced technologies, such as wearable sensors and digital twins, can provide the basis of a solution to this challenge.
  • Despite the rapid advances in genomics in the past few decades, there are obstacles remaining in our ability to engineer genomic DNA.

Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment

Retrieved on: 
Wednesday, February 21, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, SARS-CoV-2, HLA, MD, Infection, Cell, Risk, CTL, Genome, COVID, Patient, Clinical trial, TVGN, Vaccine

TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome.

Key Points: 
  • TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome.
  • Tevogen plans to assess whether TVGN 489 cells can rapidly eliminate symptoms of Long Covid.
  • Prior to launching the Long COVID clinical trial, Tevogen seeks to address whether Long COVID occurs more commonly with certain HLA types and less commonly with others, or whether Long COVID occurs randomly in the population regardless of HLA.
  • I am highly optimistic that TVGN 489 will offer a meaningful solution for both acute and Long COVID patients,” said Neal Flomenberg, MD, Tevogen’s Chief Scientific Officer.

Synthetic DNA Sheds Light on Mysterious Difference Between Living Cells at Different Points in Evolution

Retrieved on: 
Wednesday, March 6, 2024
Human services, Nature, Engineering, Fungus, Sol, Nonsense, Doctor of Philosophy, HPRT1, CpG, DNAS, Health, Noise, Genetic code, Thymine, Letter, Cell, Factorization of polynomials, RNA, Human, Adenosine, NYU Langone Health, Genome, Protein, Gene, Genomics, Genetics, Accident, NHGRI, DNA, Mouse, Vaccine

Is it just noise, a side effect of evolution, or does it have functions?

Key Points: 
  • Is it just noise, a side effect of evolution, or does it have functions?
  • A research team at NYU Langone Health sought to answer the question by creating a large, synthetic gene, with its DNA code in reverse order from its natural parent.
  • Then they put synthetic gene into yeast and mouse stem cells and watched transcription levels in each.
  • The study authors use yeast cells to assemble long DNA sequences in a single step, and then deliver the them into mouse embryonic stem cells.

Why some RNA drugs work better than others

Retrieved on: 
Wednesday, March 6, 2024
Infant, Research, Drug development, Krainer, SMA, RNA, Risdiplam, Genome, Patient, SPRING, Pancreatic cancer, Cold Spring Harbor Laboratory, RNA splicing, CSHL, Vaccine

CSHL Associate Professor Justin Kinney, Krainer, and postdoc Yuma Ishigami have figured out why some splicing-based drugs tend to work better than others.

Key Points: 
  • CSHL Associate Professor Justin Kinney, Krainer, and postdoc Yuma Ishigami have figured out why some splicing-based drugs tend to work better than others.
  • To better understand how this drug works, the Kinney and Krainer labs analyzed risdiplam's interactions with RNA.
  • "Our new study provides insights into the action and specificity of splice-modifying drugs," Krainer says.
  • "This should facilitate the development of more effective drugs and drug combinations for a variety of diseases."

Droplet-based Whole Genome Amplification: Successfully Sequencing Minute Amounts of Mycobacterium Tuberculosis DNA, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, February 28, 2024
Whole genome sequencing, ONT, Tree (graph theory), Drug resistance, University of Antwerp, TB, WGS, Research, University, Health, Genome, MAGMA, Nanopore sequencing, Mycobacterium tuberculosis, Tuberculosis, DNA, Oxford Nanopore Technologies, Vaccine

TORONTO, Feb. 28, 2024 /PRNewswire-PRWeb/ -- Whole genome sequencing (WGS) is crucial for tuberculosis (TB) surveillance, but its implementation in patient care is hindered by the limited amount of Mycobacterium tuberculosis (Mtb) in clinical specimens and the slow growth of Mtb.

Key Points: 
  • In this free webinar, delve into the significance of whole genome sequencing (WGS) in advancing tuberculosis (TB) surveillance.
  • Attendees will learn how droplet-based multiple displacement amplification (dMDA) coupled with WGS helped successfully sequence minute amounts of Mtb DNA.
  • The control and 5 pg input dMDA samples underwent nanopore sequencing and were analysed using nanorate sequencing (Nanoseq) and TB-profiler.
  • Register for this webinar today to gain insights into how dMDA amplification coupled with whole genome sequencing helped successfully sequence minute amounts of Mtb DNA.

Molly He Honored as a CNBC Changemaker in Inaugural List of Women Transforming Business

Retrieved on: 
Wednesday, February 28, 2024
Paper, Molly, SAN, Doctor of Philosophy, SVP, Female, Venrock, COVID, Genome, CNBC, Science, Research, Management

As a first-generation Asian female leader, Molly was honored by CNBC for spearheading a remarkable undertaking to democratize sequencing and biological tools globally.

Key Points: 
  • As a first-generation Asian female leader, Molly was honored by CNBC for spearheading a remarkable undertaking to democratize sequencing and biological tools globally.
  • Her work is a reflection of her commitment to collaborative science through fairness and accessibility for the research community.
  • "Today is a great honor and a true testament to the journey the Element team has embarked on together since the company's founding," Molly He said.
  • "We are incredibly proud to see Molly recognized on CNBC's inaugural Changemakers list," said Bryan Roberts, PhD, partner at Venrock and member of the Element Biosciences Board of Directors.

Armonica Technologies announces Emily Milsovic joins Board of Directors

Retrieved on: 
Monday, February 26, 2024
SAN, Doctor of Philosophy, Molecular medicine, Growth, Medicine, Medtech, Genome, Knowledge, Biotechnology, Glass harmonica, DNA, Fine chemical

SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Armonica Technologies, Inc., a pioneer in sample-prep free direct optical DNA sequencing, today announced the appointment of biotech veteran Emily Milsovic to the Board of Directors.

Key Points: 
  • SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Armonica Technologies, Inc., a pioneer in sample-prep free direct optical DNA sequencing, today announced the appointment of biotech veteran Emily Milsovic to the Board of Directors.
  • Armonica Technologies is a MedTech company focused on developing its advanced long-read sequencing platform for precision medicine applications.
  • "I'm thrilled that Emily recently joined the Armonica team.
  • "I'm excited to join the Armonica Board of Directors because I'm passionate about technologies that can transform genomics.